194 related articles for article (PubMed ID: 19337530)
1. Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes.
Israel MK; Istvan E; Baron MA
Vasc Health Risk Manag; 2008; 4(6):1167-78. PubMed ID: 19337530
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
Horton ES; Foley JE; Shen SG; Baron MA
Curr Med Res Opin; 2004 Jun; 20(6):883-9. PubMed ID: 15200747
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
[TBL] [Abstract][Full Text] [Related]
4. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes.
Schwarz SL; Gerich JE; Marcellari A; Jean-Louis L; Purkayastha D; Baron MA
Diabetes Obes Metab; 2008 Aug; 10(8):652-60. PubMed ID: 17941876
[TBL] [Abstract][Full Text] [Related]
5. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
Horton ES; Clinkingbeard C; Gatlin M; Foley J; Mallows S; Shen S
Diabetes Care; 2000 Nov; 23(11):1660-5. PubMed ID: 11092289
[TBL] [Abstract][Full Text] [Related]
6. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
Fonseca V; Grunberger G; Gupta S; Shen S; Foley JE
Diabetes Care; 2003 Jun; 26(6):1685-90. PubMed ID: 12766094
[TBL] [Abstract][Full Text] [Related]
7. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.
Marre M; Van Gaal L; Usadel KH; Ball M; Whatmough I; Guitard C
Diabetes Obes Metab; 2002 May; 4(3):177-86. PubMed ID: 12047396
[TBL] [Abstract][Full Text] [Related]
8. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.
Salas M; Ward A; Caro J
Clin Ther; 2002 Oct; 24(10):1690-705. PubMed ID: 12462297
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring.
Abrahamian H; Francesconi M; Loiskandl A; Dzien A; Prager R; Weitgasser R
Diabetes Technol Ther; 2004 Feb; 6(1):31-7. PubMed ID: 15000767
[TBL] [Abstract][Full Text] [Related]
10. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis.
Del Prato S; Heine RJ; Keilson L; Guitard C; Shen SG; Emmons RP
Diabetes Care; 2003 Jul; 26(7):2075-80. PubMed ID: 12832316
[TBL] [Abstract][Full Text] [Related]
12. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
Hirschberg Y; Karara AH; Pietri AO; McLeod JF
Diabetes Care; 2000 Mar; 23(3):349-53. PubMed ID: 10868864
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
Saloranta C; Hershon K; Ball M; Dickinson S; Holmes D
J Clin Endocrinol Metab; 2002 Sep; 87(9):4171-6. PubMed ID: 12213867
[TBL] [Abstract][Full Text] [Related]
14. Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84.
Weaver JU; Robertson D; Atkin SL
Diabetes Obes Metab; 2004 Sep; 6(5):344-52. PubMed ID: 15287927
[TBL] [Abstract][Full Text] [Related]
15. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
Ristic S; Collober-Maugeais C; Cressier F; Tang P; Pecher E
Diabetes Obes Metab; 2007 Jul; 9(4):506-11. PubMed ID: 17587393
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions.
Schatz H; Schoppel K; Lehwalder D; Schandry R
Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):262-6. PubMed ID: 12951631
[TBL] [Abstract][Full Text] [Related]
17. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
Ristic S; Collober-Maugeais C; Pecher E; Cressier F
Diabet Med; 2006 Jul; 23(7):757-62. PubMed ID: 16842480
[TBL] [Abstract][Full Text] [Related]
18. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin.
Gerich J; Raskin P; Jean-Louis L; Purkayastha D; Baron MA
Diabetes Care; 2005 Sep; 28(9):2093-9. PubMed ID: 16123472
[TBL] [Abstract][Full Text] [Related]
19. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
Zhou J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
Diabetes Technol Ther; 2013 Jun; 15(6):481-8. PubMed ID: 23631607
[TBL] [Abstract][Full Text] [Related]
20. [Nateglinide].
Notoya Y; Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():371-5. PubMed ID: 12387020
[No Abstract] [Full Text] [Related]
[Next] [New Search]
